SBIR Phase I: A high throughput microfluidic platform to accelerate biomanufacturing transitions in the COVID-19 response

SBIR 第一阶段：高通量微流控平台，可加速应对 COVID-19 的生物制造转型

• 批准号: 2032448
• 负责人: Konstantinos Tsioris
• 金额: $ 25.6万
• 依托单位: ONECYTE BIOTECHNOLOGIES, INC.
• 依托单位国家: 美国
• 项目类别: Standard Grant
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-09-01 至 2021-08-31
• 项目状态: 已结题
• 来源: https://www.nsf.gov/awardsearch/showAward?AWD_ID=2032448&HistoricalAwards=false
• 关键词: SBIR; Phase; throughput; microfluidic; platform

The broader impact/commercial potential of this Small Business Innovation Research (SBIR) Phase I project aims to address a key challenge in the response to COVID-19, namely manufacturing sufficient quantities of novel therapeutics and vaccines. This project can shorten the development times of drugs by as much as 6 months, accelerating translation of new therapeutics. This technology will also enable more testing, thereby increasing the performance and potentially reducing the side effects of these drugs.This SBIR Phase I project advances the manufacturing of biologics, which starts with a high performing clonal cell line derived (by definition) from a single cell. Developing such a cell line today takes up to 6 months due to iterative screening and testing to assure quality and performance. The proposed project aims to enable selection of a high performing cell clone in one day compared to many months by using a proprietary single cell proteomics platform, at an unprecedented throughput rather than lengthy, iterative selection, clonal expansion and analytics.This award reflects NSF's statutory mission and has been deemed worthy of support through evaluation using the Foundation's intellectual merit and broader impacts review criteria.

这项小企业创新研究（SBIR）第一阶段项目的更广泛影响/商业潜力旨在解决应对COVID-19的一项关键挑战，即生产足够数量的新疗法和疫苗。该项目可缩短药物开发时间多达6个月，加速新疗法的转化。这项技术还可以进行更多的测试，从而提高这些药物的性能，并有可能减少这些药物的副作用。SBIR一期项目推进了生物制剂的生产，从单细胞衍生的高性能克隆细胞系开始（根据定义）。目前，开发这样的细胞系需要长达6个月的时间，因为需要反复筛选和测试以确保质量和性能。该项目旨在通过使用专有的单细胞蛋白质组学平台，在一天内选择一个高性能的细胞克隆，而不是几个月，以前所未有的吞吐量，而不是漫长的，迭代的选择，克隆扩增和分析。该奖项反映了美国国家科学基金会的法定使命，并通过使用基金会的知识价值和更广泛的影响审查标准进行评估，被认为值得支持。